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Abstract
Cancer care has greatly improved 
in the last few decades, as evidenced 
by a 22% decline in the overall 
cancer-related death rate in the 
United States since 1991. However, 
the question presents itself whether 
rural residents, for whom the latest 
advancements are not as accessible, 
are also realizing these benefits as 
much as their urban counterparts. The 
aim of this study is to provide a 
review of the literature regarding the 
disparities in cancer care facing rural 
Appalachia and specifically West 
Virginia (WV) as well as possible 
solutions towards bridging this gap. 
We find that WV has a higher cancer 
incidence and mortality rate with 
fewer oncologists per resident, while 
rural areas in general have lower 
clinical trial participation and 
different treatment regimens. Though 
programs have been put in place such 
as mobile mammography clinics and 
local outreach, more work can be 
done in WV in the realms of 
teleoncology, virtual tumor boards, 
patient support groups, and physician 
training programs.
Introduction
In West Virginia (WV), the overall 
cancer-related death rate from 
2008-2012 was 191.1 deaths per 
100,000 residents, significantly 
higher than the national average 
of 166.4 (Table 1).1 Though trends 
suggest that overall cancer-related 
death rates are falling both in WV 
and nationally, the 12% relative 
decline noted in WV from 1990 to 
2011 lags behind the 22% national 
average decline, placing it second 
lowest behind Oklahoma at 9%.2 
This suggests a disparity in cancer 
care between WV and the nation 
at-large, which has prompted 
many studies examining this issue. 
Furthermore, such disparities have 
direct implications for WV given 
that it has the third highest national 
proportion of the elderly (those 65 
years of age or older) at 17.3% of 
its population, and the elderly tend 
to have more cancer diagnoses.3 As 
the segment of the aging population 
continues to increase so will the 
burden of cancer care in WV and the 
US. In fact, by 2030, total projected 
cancer incidence is estimated to 
increase by roughly 45% primarily 
driven by a 67% increase in 
cancer diagnoses of the elderly.4
Rural Cancer Incidence 
Residents of WV from 2008-2012 
had age-adjusted all-site cancer 
incidences of roughly 456.3 new 
diagnoses per 100,000 residents 
per year, which is significantly higher 
than the national rate of 432.3.1 
Cancer sites with significantly higher 
incidence rates in WV include lung, 
colorectal, bladder, kidney and 
renal pelvis, and cervical cancers 
(interestingly, prostate cancer had 
a significantly lower incidence rate). 
A variety of factors that differentiate 
residents of Appalachia (defined 
as regions in Alabama, Georgia, 
Kentucky, Maryland, Mississippi, 
New York, Ohio, Pennsylvania, 
South Carolina, Tennessee, Virginia, 
and all of WV) from other Americans 
likely contribute, including lower 
income and education levels as 
well as higher rates of poor health 
behaviors (ie. tobacco use).5,6 
Even among their Appalachian 
counterparts, WV residents have 
a higher incidence of particular 
cancers, such as cervical cancer.7 
Environmental exposures may 
play a role in increased cancer 
incidence in WV, as residents of 
rural counties with mountaintop 
coal mining have been found to 
have increased community cancer 
risk.8 However, this merits more 
robust study given that results of 
research on this topic are mixed.9
Interestingly, when looking at 
cancer incidence rates at the 
county level in WV, urban counties 
constitute the top three spots 
and rural counties the bottom 
two (using the Health Resources 
Service Administration’s definition 
of rural).10 Hampshire, Cabell, and 
Wirt counties have the highest 
incidence rates at 594.8 (95% CI: 
553.7 - 638.3), 590.1 (95% CI: 
569.9 - 610.9), and 572.1 (95% CI: 
493.7 - 660.1) cases per 100,000 
residents, whereas Doddridge 
(336.7; 95% CI: 283.0 - 398.2) 
and Grant (343.5; 95% CI: 303.3 - 
387.9) counties have the lowest.11 
Objectives
1. To describe the disparities in cancer care in West Virginia
2. To recognize possible solutions to cancer care disparities
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Further research is needed to 
investigate the factors such as 
greater amounts of air pollution that 
might account for higher cancer 
incidence in urban counties.
Physician Supply and 
Mortality
Also of relevance to treatment of 
cancer is the supply and training of 
physicians. At the moment, 10% of 
physicians practice in rural areas, 
and only 4.8% of newly trained 
physicians are choosing to practice 
in such areas.12 In WV, there are 
currently 76 oncologists, which 
for a population of roughly 1.85 
million translates to an oncologist 
density of 4.1 specialists per 
100,000 residents.13 This falls on 
the lower end of the rest of the 
country, and of particular note is 
the scarcity of cancer specialists 
in many counties throughout the 
state (Figure 1, Kirkwood et al.).14
The importance of physician 
supply at the county-level to 
cancer survival is well supported 
in the literature. Aneja et al. has 
found that the presence of one 
radiation oncologist in a county 
results in a nearly 5% decline in 
prostate-cancer related deaths,15 
and even more robust mortality 
reductions have been noted for 
esophageal (22-79%) pancreatic 
(27-51%), and colorectal (12-47%) 
cancers.16,17,18 The presence of 
one urologist in a county also may 
lead to a roughly 20% reduction in 
prostate and bladder cancer-related 
Rates (per 100,000 residents) United States of America West Virginia WV / National Ratios
All-Site Cancer Incidence Rate 432.3 456.3 1.056 (95% CI: 1.034 - 1.079)
All-Site Cancer Mortality Rate 166.4 191.1 1.149 (95% CI: 1.011 - 1.187)  
Lung and Bronchus Cancer Incidence Rate 60.4 77.1 1.278 (95% CI: 1.212 - 1.345)
Lung and Bronchus Cancer Mortality Rate 45.0 59.6 1.324 (95% CI: 1.248 - 1.405)
Breast Cancer Incidence Rate 122.1 115.2 0.944 (95% CI: 0.904 - 0.985)
Breast Cancer Mortality Rate 21.3 22.3 1.047 (95% CI: 0.950 - 1.153)
Prostate Cancer Incidence Rate 105.1 90.4 0.860 (95% CI: 0.820 - 0.902)
Prostate Cancer Mortality Rate 19.6 16.0 0.807 (95% CI: 0.720 - 0.904)
Colorectal Cancer Incidence Rate 38.9 44.3 1.137 (95% CI: 1.062 - 1.219)
Colorectal Cancer Mortality Rate 14.7 17.2 1.171 (95% CI: 1.049 - 1.308)
Bladder Cancer Incidence Rate 20.2 24.5 1.213 (95% CI: 1.106 - 1.330)
Bladder Cancer Mortality Rate 4.4 4.5 1.018 (95% CI: 0.821- 1.263)
Kidney and Renal Pelvis Cancer Incidence Rate 15.8 18.7 1.182 (95% CI: 1.063 - 1.313)
Kidney and Renal Pelvis Cancer Mortality Rate 3.8 3.5 0.923 (95% CI: 0.724 - 1.178)
Cervical Cancer Incidence Rate 7.4 9.6 1.298 (95% CI: 1.120 - 1.505)
Cervical Cancer Mortality Rate 2.3 3.4 1.478 (95% CI: 1.154 - 1.895)
Table 1
Figure 1
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deaths.19 Similar trends exist for 
other cancers; for example, rural 
county residence is associated 
with a 5% increase in sarcoma-
related mortality.20 Likewise, 
residents who lived more than 50 
miles away from a gynecologic 
oncologist had a nearly 60% higher 
risk of ovarian cancer mortality.21
Thus, the establishment of training 
programs in medical oncology 
and radiation oncology is key to 
ensuring that an adequate cancer 
workforce is available. Both West 
Virginia University and Marshall 
University Schools of Medicine 
currently have medical oncology 
fellowships, though neither at the 
moment has residency programs 
in radiation oncology.22,23 
WV has significantly higher 
mortality rates for all-sites, as well 
as lung and bronchus, colorectal, 
and cervical cancers. When further 
examining the data by country, from 
2008-2012, the top four counties with 
the highest cancer-related mortality 
rates per 100,000 residents were 
Webster (248.3; 95% CI: 209.8-
292.4; urban), Wyoming (240.5; 
95% CI: 215.5-268.4; rural), Lincoln 
(240.5; 95% CI: 214.0-269.6; urban), 
and Mingo (240.4; 95% CI: 216.0-
266.9; rural) counties. Those with the 
lowest mortality-rates were Hardy 
(151.4; 95% CI: 126.7-179.9), Grant 
(129.7; 95% CI: 105.6-158.2), and 
Pendleton (127.9; 95% CI: 101.0-
161.1) counties, all of which are 
rural.2 Given that two of the top four 
are urban counties, this suggests 
that physician supply/proximity may 
be only one of a variety of factors 
that account for the higher mortality 
rates observed in WV. Even so, 
the effect of access to oncologists 
and radiation oncologists on cancer 
death rates has been supported 
by many studies in the literature.
Prevention and Treatment 
of Cancer in Rural America
The incidence of cancer is 
generally higher in Appalachia.24 
Additionally, mortality to incidence 
ratios are higher, specifically for 
breast, cervical, and prostate 
cancers, which some attribute 
to a lack of federally qualified 
health centers that provide 
cancer screening.25 Lower rates 
of screening in rural areas are 
documented in the literature. For 
example, in Kentucky, residents 
of Appalachian counties were half 
as likely to have a colonoscopy or 
sigmoidoscopy performed within 
the past 10 years as their non-
Appalachian counterparts.26 As many 
screenings, such as colonoscopies, 
often are dependent upon physician 
recommendation, it is likely that 
factors such as lack of access to 
primary care contribute to these 
findings. This has implications for 
delayed presentation and initial 
staging of cancer. For example, 
white and African-American women 
residing in rural Mississippi were 4% 
and 19% more likely, respectively, 
to be diagnosed with advanced 
regional/distant breast cancer 
than their urban counterparts.27 
Similarly, late-stage diagnosis of 
melanomas is associated with areas 
of lower median education levels, 
as is the case in rural counties.28 
Many studies have also focused 
on differences in breast cancer 
treatment in rural areas and 
implications for survival. Freeman 
et al. showed that following 
surgery, early-stage breast cancer 
patients in Appalachian counties of 
Kentucky are less likely to receive 
adjuvant radiation therapy,29 which 
is associated with a 12.1% decline 
in 10 year survival.30 This has been 
confirmed by other studies and is 
attributed to a paucity of radiation 
oncologists as well as radiation 
therapy facilities.31 Additionally, 
patients in rural areas may be 
less likely to receive adjuvant 
chemotherapy. In a study of breast 
cancer patients in Wisconsin having 
similar likelihoods of recurrence, 
Andreason et al. revealed only 
36% of rural patients underwent 
adjuvant chemotherapy compared 
to 52% of those in urban areas.32 All 
of these factors likely contribute to 
changes in breast cancer mortality 
in rural areas. Though the number 
of breast cancer-related deaths in 
Appalachia have declined by 17.5% 
from 1969-2007, this reduction is 
not as robust as that observed in 
non-Appalachian counties (28.3%).33
Variations in treatment 
regimens for rural patients also 
exist for other cancers. Notably, 
retrospective studies have found 
that only 46.5% of elderly lung 
cancer patients in rural and 
medically-underserved areas of 
WV received guideline-concordant 
care, which was associated 
with a nearly one year decline 
in survival outcomes.34 Baldwin 
et al. observed that rural cases 
of early-stage prostate cancers 
are 3.4% less likely to receive 
standard treatment regimens.35 
Similarly, rural patients with stage 
III colon cancer who had to travel 
50 miles or greater were less likely 
to receive adjuvant treatment than 
those closer to treatment sites.36
Clinical Trials in Appalachia
Also of importance is whether 
rural patients are given the 
opportunity to participate in clinical 
trials, which may provide novel 
treatment strategies for cancer 
sites with poorer prognoses such 
as brain neoplasms and other 
cancers that have progressed on 
standard therapy. Prior studies 
have demonstrated that areas 
with higher socioeconomic levels, 
approved cancer programs, and 
greater oncologist density (all of 
which are significantly lower in rural 
Appalachia) are associated with 
increased clinical trial participation.37 
Furthermore, research shows that 
rural residents are much less likely 
to be recruited for such trials.38
There are barriers to involving 
rural participants in clinical trials. A 
survey of principal investigators’(PIs) 
attitudes at 5 academic centers 
in South Carolina found that 
PIs perceive rural residents as 
being the most difficult to recruit. 
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Reaching out through local doctors 
for participants was not common, 
and it was very uncommon to look 
for other means (ie. faith-based 
organizations, television, radio, 
etc.) of participant recruitment.39 
Furthermore, PIs perceive rural 
residents as having less knowledge 
and understanding of clinical trials.40 
From the perspective of patients, 
residents of rural areas often believe 
that clinical trials are deceptive in 
nature, lack general knowledge 
regarding the purpose of clinical 
trials, and are often dissuaded by 
complicated informed consent forms. 
These barriers make rural residents 
less likely to participate in clinical 
trials relative to urban residents.41,42
Review of Attempted 
Solutions 
Telemedicine, or the use of 
telecommunication to provide 
medical care from a distance, may 
have a role in improving cancer care 
in rural areas. Perhaps the most 
prominent example of teleoncology 
in the US is the University of Kansas 
Medical Center’s (UKMC), which 
reported successful implementation 
of remote supervision of 
chemotherapy.43 Patients come 
to a local health site where a 
nurse follows directions for the 
physical exam from the oncologist 
communicating via video. Relevant 
information, such as labwork, 
radiographs, etc., is then faxed to 
the corresponding oncologist for 
continuous review and monitoring. To 
provide incentives for chemotherapy 
administration, this system had 
local sites collect revenues. Costs 
in this model decreased with time 
and steadily approached those 
of traditional encounters. Patient 
satisfaction from other models of 
telemedicine was positive overall 
following treatment.44,45 Roughly 
half of patients in the UKMC study 
had some concerns regarding 
nurses rather than physicians 
performing certain aspects of the 
physical exam, though all patients 
surveyed expressed satisfaction 
with the model overall. Telemedicine 
may also be particularly helpful 
for post-treatment follow-ups. For 
example, a study done in British 
Columbia, Canada, found that a 
telemedicine program for colorectal 
cancer patients with geographic 
barriers led to a rise in the number 
of follow-ups with 80% of patients 
satisfied with the program.46
Of concern with telemedicine is 
the safety of remotely monitoring 
chemotherapy. Pathmanathan et al. 
compared the incidence of adverse 
effects (ie. febrile neutropenia, 
diarrhea, vomiting) between rural 
and urban patients in Australia with 
either metastatic colorectal or node-
positive breast cancers undergoing 
chemotherapy treatment over a 24 
month period, and no significant 
difference in the occurrence of any 
side effects was noted.47 Similarly, 
ambulatory cancer patients in 
Singapore were monitored via a 
pharmacist-run teleoncology service, 
which utilized a short-message-
service algorithm to guide patients 
thru a decision-making process 
to provide information should a 
80 West Virginia Medical Journal www.wvsma.org
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pharmacist not be available to talk. 
This trial had 73% adherence, 
and of those who completed the 
service, nearly 2/3 of patients 
were satisfied.48 These results 
support the feasibility and safety 
of chemotherapy administration 
and monitoring via telemedicine.
Unlike chemotherapy, radiation 
therapy is more difficult to provide 
remotely given high financial 
barriers to obtaining the necessary 
equipment. As such, rural patients 
travel to large referral centers 
to receive radiation, though 
telemedicine may be of use in 
reducing trips for treatment planning 
and simpler protocols (ie. external 
beam radiation as opposed to 
brachytherapy, which requires 
more active surveillance). In Japan, 
one study was able to accurately 
transmit radiotherapy plans from a 
workstation at a cancer center to 
an affiliated hospital 50 km away 
to allow for editing of beam data 
remotely.49 Prior studies conducted 
in Japan also demonstrated 
accurate reproducibility of planned 
isocenters (the point at which 
beams of radiation converge) for 
3D-conventional radiotherapy.50 
Similar successful attempts at a 
teleradiotherapy network were 
reported in Germany for treatment 
of Hodgkin’s lymphoma by means of 
high-quality transfer of imaging data 
and real-time teleconferences.51
Unique to cancer care, 
particularly for more difficult and 
rare cases, are tumor boards. Thus, 
telemedicine’s application led to 
the advent of virtual tumor boards 
(VTBs) to allow local providers 
the opportunity to consult with 
specialists. As an example, the 
University of North Carolina (UNC) 
offered this option to community 
physicians. Ninety-one percent 
of participating UNC oncologists 
felt that the presenting physician’s 
questions were addressed and 
that the information provided was 
adequate for discussion, and 19% 
felt that VTBs were less likely to 
lead to a consensus on treatment. 
Furthermore, only 9% experienced 
some sort of technology glitch 
during meetings. VTBs seem 
to be a viable and satisfactory 
option, though noted barriers 
include a lack of time for such 
meetings.52 Other VTB initiatives 
by Baylor and in the UK have been 
implemented with high physician 
satisfaction.53,54 VTBs have been 
noted to increase the likelihood that 
cases from community centers are 
discussed at tumor boards, expedite 
the process of interdisciplinary 
discussion, and reduce travel 
burden for rural providers.55 
Telemedicine also has the 
potential to improve management 
of cancer-associated mental health 
issues. In rural areas, patients do 
not have access to support groups 
or counselors. A virtual connection of 
patients facing similar circumstances 
to address associated symptoms 
such as depression and pain 
could be helpful. As an example, 
a Stanford study found that breast 
cancer patients in rural areas 
showed significant decreases in 
both depression as well as post-
traumatic stress disorder (PTSD) 
symptoms after participating in a 
videoconference support group.56 
The Indiana Cancer Pain and 
Depression Trial (INCPAD) noted 
similar results as patients who 
received telecare management 
via telephone and automated 
symptom monitoring had declines 
in depression and pain scores.57 
Other initiatives aim at educating 
providers and patients about 
cancer care through developing 
networks between community 
stakeholders and cancer providers. 
Of most relevance to WV is the 
Appalachian Community Cancer 
Network (ACCN), a National Cancer 
Institute-designated Community 
Network Program with partners 
in Kentucky, Ohio, Pennsylvania, 
Virginia, and WV. In WV, the ACCN 
has worked closely with the Webster 
County Cancer Education Project 
to provide breast and cervical 
cancer screening as well as the 
Wetzel County Cancer Coalition to 
assist patients with transportation 
for treatment.58 The network also 
provides guidance, support, and 
mini-grants to organizations facing 
difficulty in implementing educational 
interventions.59 WVU also has 
a mobile mammography clinic, 
which in 2009 was able to provide 
360 mammograms in 20 counties 
across the state, with roughly 
50% of women from underserved 
backgrounds, and by 2015 had 
provided services to nearly 8,700 
women.60,61 A statewide network has 
also been established to involve 
more WV residents in clinical trials.62
Outside of WV, there are other 
successful rural outreach and 
educational programs. Physician 
awareness programs in Arkansas 
have led to significant increases 
in screening recommendations for 
prostate, breast, and colorectal 
cancers.63,64 Similarly, in Mississippi, 
an educational outreach program 
had 883 community volunteers 
complete 16 hours of training 
in cancer awareness and the 
importance of clinical trials. The 
volunteers also attended monthly 
continuing education meetings 
to disseminate information in 
their respective communities 
regarding screenings provided 
by the state’s Department of 
Health. Following the program, 
pap smears increased 23% and 
mammograms increased 117%.65 
Conclusion
Disparities in rural Appalachia 
with regards to cancer incidence, 
mortality, and treatment are well 
documented. To address the lack 
of specialists practicing in rural 
WV, a variety of education and 
screening outreach programs have 
been implemented and met with 
success. However, other possible 
solutions, notably telemedicine, 
virtual tumor boards, patient support 
programs, and physician training 
programs in radiation oncology 
have yet to be implemented or 
documented in WV. Success with 
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these initiatives in areas facing 
similar challenges suggests more 
work can be done to bridge the gap 
in cancer care for West Virginians.
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